RTP Mobile Logo
Breakfast with the Investigators: Systemic Management of Melanoma
Released August 2016

Proceedings from a CME symposium held at the 2016 ASCO Annual Meeting. Featuring perspectives from Drs Keith T Flaherty and Jeffrey Weber. (Video Program)

CE Disclosures and Faculty Information

    This program is intended for medical oncologists, hematology-oncology fellows and other allied healthcare professionals involved in the treatment of melanoma.

    Despite increased awareness and extensive attempts to publicize risk factors and screening, current estimates suggest that 76,380 men and women will be diagnosed with melanoma and 10,130 individuals will die from the disease in 2016 within the United States alone. Because of its cutaneous location and its high metastatic potential, management of melanoma remains a major challenge. Clinicians are routinely faced with the task of identifying which patients are appropriate candidates for adjuvant therapy and with what specific intervention, and until recently treatments for advanced disease had been relatively limited in their overall effectiveness. However, unprecedented new strides have been made in defining molecular mechanisms of critical importance to melanoma development, progression and metastasis. Similarly, increased understanding of the pathophysiology behind melanoma’s traditional chemoresistance has resurrected a keen research focus on therapeutic immune system modulation. In this regard, pivotal presentations over the past several years have reflected the success of these efforts, paving the way for the first new FDA-endorsed treatment options for patients with metastatic melanoma in more than a decade and the expanded role of novel targeted agents in the treatment of advanced disease. All of these new therapeutic options have been heralded as major breakthroughs by the melanoma community but have challenged practicing clinicians to quickly understand how best to safely integrate them into current management algorithms.

    These video proceedings from a CME symposium held during the 2016 ASCO Annual Meeting feature discussions with leading researchers with an expertise in melanoma regarding actual cases from their practices and the published data that drive clinical decision-making for patients in those and diverse other situations. By providing information on the latest research developments and their potential application to routine practice, this activity is designed to assist medical oncologists, hematology-oncology fellows and other healthcare providers with the formulation of up-to-date clinical management strategies.


    • Appreciate the recent FDA indication for ipilimumab as adjuvant therapy, and identify patients for whom this therapeutic approach should be considered after surgical removal of primary melanoma.
    • Consider age, performance status and other disease-related factors to guide the selection of first- and later-line therapy for patients with metastatic BRAF wild-type melanoma.
    • Appraise clinical trial evidence to identify the role of available immunotherapeutic approaches in the management of metastatic BRAF mutation-positive melanoma.
    • Recall existing and emerging research demonstrating the effect of combining BRAF and MEK inhibitors for patients with BRAF mutation-positive metastatic melanoma, and use this information to guide treatment planning.
    • Recognize immune-related adverse events associated with immune checkpoint inhibitors, and offer supportive management strategies to minimize and/or ameliorate these side effects.
    • Recall new data with investigational agents and strategies demonstrating promising activity in melanoma, and discuss ongoing trial opportunities with eligible patients.

    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CME credit is no longer available for this issue


    CME credit is no longer available for this issue


    CME credit is no longer available for this issue

    This CME activity consists of a video component.

    CME credit is no longer available for this issue

    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

    Keith T Flaherty, MD
    Director, Henri and Belinda Termeer Center for Targeted Therapies
    Massachusetts General Hospital Cancer Center
    Professor, Harvard Medical School
    Director of Developmental Therapeutics
    Boston, Massachusetts

    Advisory Committee: Amgen Inc, Bristol-Myers Squibb Company, Merck, Sanofi; Consulting Agreements: Boehringer Ingelheim Pharmaceuticals Inc, Genentech BioOncology, GlaxoSmithKline, Novartis Pharmaceuticals Corporation, Roche Laboratories Inc, Takeda Oncology; Contracted Research: Novartis Pharmaceuticals Corporation, Sanofi.

    Jeffrey Weber, MD, PhD
    Deputy Director
    Laura and Isaac Perlmutter Cancer Center
    Professor of Medicine
    NYU Langone Medical Center
    New York, New York

    Advisory Committee: Amgen Inc, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Daiichi Sankyo Inc, Genentech BioOncology, GlaxoSmithKline, Merck, Novartis Pharmaceuticals Corporation, Roche Laboratories Inc; Consulting Agreements: Altor Bioscience Corp, Bristol-Myers Squibb Company, cCAM Biotherapeutics, Celldex Therapeutics, CytomX Therapeutics, GreenPeptide Co Ltd, Ichor Medical Systems, Immune Design, Medivation Inc; Stock Ownership: Altor Bioscience Corp, cCAM Biotherapeutics, Celldex Therapeutics..

    MODERATOR — Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma, Agendia Inc, Amgen Inc, Array BioPharma Inc, Astellas Pharma Global Development Inc, AstraZeneca Pharmaceuticals LP, Baxalta Inc, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Pharma Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, CTI BioPharma Corp, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, Exelixis Inc, Foundation Medicine, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Janssen Biotech Inc, Jazz Pharmaceuticals Inc, Lilly, Medivation Inc, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, NanoString Technologies, Natera Inc, Novartis Pharmaceuticals Corporation, Novocure, Onyx Pharmaceuticals, an Amgen subsidiary, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Regeneron Pharmaceuticals, Sanofi, Seattle Genetics, Sigma-Tau Pharmaceuticals Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Teva Oncology, Tokai Pharmaceuticals Inc and VisionGate Inc.

    RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no relevant conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from Array BioPharma Inc, Bristol-Myers Squibb Company, Genentech BioOncology and Merck.

    Hardware/Software Requirements:
    A high-speed Internet connection
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 7 or later, Firefox 3.0 or later, Chrome, Safari 3.0 or later
    Adobe Flash Player 10.2 plug-in or later
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Last review date: August 2016
    Expiration date: August 2017

Acknowledge and close

Watch video
(WIFI is recommended for best performance):
Video segments: